

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | 1 | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | 1 | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | — | 1 | 1 | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | — | 1 | 1 | — | — | 1 |
| Drug common name | Odronextamab |
| INN | odronextamab |
| Description | Odronextamab (REGN1979) is a CD20 x CD3 bispecific monoclonal antibody that is developed by Regeneron Pharmaceuticals for B-cell non-Hodgkin lymphoma.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298084 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB16684 |
| UNII ID | 8R5CM46UIO (ChemIDplus, GSRS) |

